Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628715 | 0.88 | SGK1 (0.56) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL14066176 | 0.84 | SGK1 (0.73) | SGK1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL13628717 | 0.82 | SGK1 (0.73) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL13628696 | 0.80 | SGK1 (0.71) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL13628842 | 0.80 | SGK1 (0.61) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL13628704 | 0.79 | SGK1 (0.69) | SGK1TDP1MEN1KMT2AMAPT | |
| SCHEMBL13628711 | 0.79 | SGK1 (0.69) | SGK1MEN1KMT2AMAPTLMNA | |
| SCHEMBL14066128 | 0.79 | SGK1 (1.00) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL13628719 | 0.79 | SGK1 (0.69) | SGK1POLBTDP1MEN1KMT2A | |
| SCHEMBL13628721 | 0.79 | SGK1 (0.69) | SGK1POLBTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | GRK4, SGK1, SGK2 | SGK1 2/4885POLB 4702/4885TDP1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.